发明名称 INHIBITION OF GSK-3 beta
摘要 The activity of NF-kB is modulated through the effects of GSK-3 on NK-kB activity. Inhibition or down-regulation of GSK-3 results in decreased NF-kB activity. Inappropriate activation of NF-kB has been linked to inflammation and hyperproliferative disorders. Development of modulatory strategies provide a novel therapeutic tool for the treatment or prevention of various diseases. Methods are also provided for enhanced killing of tumor cells through the sensitization action of GSK-3 inhibition, when administered in conjunction with apoptosis inducing ligands of TNFR1. Transgenic animals defective in GSK-3 function are also provided.
申请公布号 WO0147533(A2) 申请公布日期 2001.07.05
申请号 WO2000CA01578 申请日期 2000.12.21
申请人 THE ONTARIO CANCER INSTITUTE;HOEFLICH, KLAUS;LUO, JUAN;WOODGETT, JIM 发明人 HOEFLICH, KLAUS;LUO, JUAN;WOODGETT, JIM
分类号 A01K67/027;A61K31/00;A61K31/19;A61K31/704;A61K38/19;A61K45/00;A61P1/04;A61P3/10;A61P7/08;A61P9/00;A61P9/10;A61P11/00;A61P11/06;A61P13/12;A61P17/06;A61P19/02;A61P21/04;A61P25/00;A61P27/16;A61P29/00;A61P31/04;A61P31/18;A61P35/00;A61P37/02;A61P43/00;C07K16/24;C12N9/99;G01N33/15;G01N33/50;(IPC1-7):A61K33/14 主分类号 A01K67/027
代理机构 代理人
主权项
地址